Volume 72, Issue 12, Pages 1527-1534 (December 2007) β-Blockers improve outcomes in kidney disease patients having noncardiac vascular surgery G.M.J.M. Welten, M. Chonchol, S.E. Hoeks, O. Schouten, J.J. Bax, M. Dunkelgrün, Y.R.B.M. van Gestel, H.H.H. Feringa, R.T. van Domburg, D. Poldermans Kidney International Volume 72, Issue 12, Pages 1527-1534 (December 2007) DOI: 10.1038/sj.ki.5002554 Copyright © 2007 International Society of Nephrology Terms and Conditions
Figure 1 Kaplan–Meier estimate of overall survival by level of kidney function (CrCl) during 5.98±3.68 years of follow-up. Kidney International 2007 72, 1527-1534DOI: (10.1038/sj.ki.5002554) Copyright © 2007 International Society of Nephrology Terms and Conditions
Figure 2 Kaplan–Meier estimate of overall survival by level of kidney function (CrCl) and β-blocker therapy during 5.98±3.68 years of follow-up. —β-Blocker use; . . . . . . . . No β-blocker use. Kidney International 2007 72, 1527-1534DOI: (10.1038/sj.ki.5002554) Copyright © 2007 International Society of Nephrology Terms and Conditions